Ambea (AMBEA) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
17 Apr, 2026Executive summary
Net sales for Q4 2025 increased by 15% to SEK 4,193 million, driven by acquisitions and solid organic growth, with a strong pipeline of new care places supporting future expansion.
Adjusted EBITA/EBITDA for the quarter was SEK 347 million, with a margin of 8.3%, reflecting investments in growth and integration activities.
The company continues to invest in leadership, work environment, IT, and operational structure to support scalable growth and quality care delivery.
Active M&A activity, including the strategic acquisition of Validia and Attendo's child welfare business, expanded the Finnish platform and entered new sub-segments.
Board proposes a dividend of SEK 2.65 per share for 2025 and a new share buyback program.
Financial highlights
Net sales reached SEK 16,039 million for 2025, with a 15% increase in Q4 year-over-year, driven by 13% acquired and 4% organic growth.
Adjusted EBITA/EBITDA margin for Q4 was 8.3%, down from 9.5% in Q4 2024, due to higher investments and integration costs.
Operating cash flow increased by 19% to SEK 1.04 billion in Q4, with free cash flow for the year totaling SEK 2,052 million.
Earnings per share rose to SEK 7.95, with a proposed dividend per share of SEK 2.65, up 20%.
Net debt/adjusted EBITDA (excl. IFRS 16) was 2.3x at year-end, below the target of 3.25x.
Outlook and guidance
Growth focus remains on both organic expansion and bolt-on acquisitions, with an industry-leading pipeline of care places and higher pace of new unit openings planned.
Investments in IT, training, and leadership are expected to continue but will not impact the EBITDA margin target of 9.5%.
Margin in Vardaga may be slightly lower in early 2026 due to new openings but is expected to recover as facilities ramp up.
Stendi margins are expected to improve mid-term to 8-9% as operational efficiencies and occupancy stabilize.
Dividend policy maintained, with a proposed increase for 2025.
Latest events from Ambea
- Q1 2026 delivered 16% sales growth, margin gains, and strong expansion across all Nordic segments.AMBEA
Q1 20267 May 2026 - Strong Q2 with 42% EBITA growth, robust cash flow, and continued expansion through M&A.AMBEA
Q2 20241 Feb 2026 - Q3 2024 delivered 6% sales growth, 25% EBITA rise, and strong cash flow for expansion.AMBEA
Q3 202416 Jan 2026 - Acquisition creates the only pan-Nordic care group, expanding into Finland and boosting growth.AMBEA
M&A Announcement26 Dec 2025 - Strong growth, margin expansion, and higher dividend driven by core care segments.AMBEA
Q4 202423 Dec 2025 - Q1 2025 saw 5% sales growth, Validia acquisition, and strong cash flow for Nordic expansion.AMBEA
Q1 202526 Nov 2025 - Q2 2025 saw 16% sales growth, 15% EBITA rise, and all financial targets achieved.AMBEA
Q2 202523 Nov 2025 - Q3 net sales up 16% and adjusted EBITA up 19%, driven by Nordic growth and acquisitions.AMBEA
Q3 20255 Nov 2025